Do neurologists in Germany adhere to the national Parkinson&#39;s disease guideline?

Código QR

Do neurologists in Germany adhere to the national Parkinson&#39;s disease guideline?

Sabrina Schr&ouml;der1, Daniel Kuessner2, Guy Arnold3, York Z&ouml;llner4, Eddie Jones5, Marion Schaefer11Institute of Clinical Pharmacology, Charit&eacute; University Medicine, CCM, Berlin, Germany; 2Basilea Pharmaceutica, Basel, Switzerland; 3Department of Neurology, Sindel...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sabrina Schr&ouml;der, Daniel Kuessner, Guy Arnold, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c4824bae047e4a52a59d0c1b88daf525
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Review: management of Parkinson&#39;s disease
por: Pedrosa DJ, et al.
Publicado: (2013)

Adjunctive therapy in Parkinson&#39;s disease: the role of rasagiline
por: Gaines KD, et al.
Publicado: (2012)

Parkinson&rsquo;s disease patients&rsquo; subjective descriptions of characteristics of chronic pain, sleeping patterns and health-related quality of life
por: Skogar &Ouml;, et al.
Publicado: (2012)

Sleep disturbances in Parkinson&#39;s disease patients and management options
por: Claassen DO, et al.
Publicado: (2011)

Daytime sleepiness in elderly Parkinson&rsquo;s disease patients and treatment with the psychostimulant modafinil: A preliminary study
por: Johan L&ouml;kk
Publicado: (2010)

A neurologist’s rhombencephalitis after comirnaty vaccination. A change of perspective
por: Alexander Walter, et al.
Publicado: (2021)

Editor&#39;s choice
por: Pinder RM
Publicado: (2012)

Psychiatrists’ Understanding and Management of Conversion Disorder: A Bi-National Survey and Comparison with Neurologists
por: Dent B, et al.
Publicado: (2020)

Treatment of Parkinson&#39;s disease: nanostructured sol&ndash;gel silica&ndash;dopamine reservoirs for controlled drug release in the central nervous system
por: Tessy L&oacute;pez, et al.
Publicado: (2010)

Psychiatric disorders in primary focal dystonia and in Parkinson&rsquo;s disease
por: Fernando MV Dias, et al.
Publicado: (2011)

Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem)
por: Fereshtehnejad SM, et al.
Publicado: (2013)

Ceruloplasmin and iron in Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease: a synopsis of recent studies
por: Kristinsson J, et al.
Publicado: (2012)

Sleep disorders in Parkinson&rsquo;s disease
por: Israt Jahan, et al.
Publicado: (2009)

When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
por: Kachuck NJ
Publicado: (2011)

Parkinson's disease managing reversible neurodegeneration [Corrigendum]
por: Hinz M, et al.
Publicado: (2016)

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer&#39;s disease in the Netherlands
por: Hoogveldt B, et al.
Publicado: (2011)

Detection of retinal changes in Parkinson&#39;s disease with spectral-domain optical coherence tomography
por: Grant D Aaker, et al.
Publicado: (2010)

Did depressive symptoms affect recognition of emotional prosody in Parkinson&rsquo;s disease?
por: Adriana V&eacute;lez Feij&oacute;, et al.
Publicado: (2008)

Galantamine treatment in Alzheimer&#39;s disease: response and long-term outcome in a routine clinical setting
por: Wallin &Aring;K, et al.
Publicado: (2011)

An update on the toxicity of A&beta; in Alzheimer&rsquo;s disease
por: J&uuml;rgen G&ouml;tz, et al.
Publicado: (2008)

Bupropion interferes with the image diagnosis of Parkinson's disease
por: Lin CH, et al.
Publicado: (2017)

Economic Impact of Low Adherence to COPD Management Guidelines in Spain
por: Miravitlles M, et al.
Publicado: (2021)

The impact of nonmotor symptoms on quality of life in patients with Parkinson's disease in Taiwan
por: Liu WM, et al.
Publicado: (2015)

A case of early onset Parkinson's disease after major stress
por: Zou K, et al.
Publicado: (2013)

Beneficial effect of pramipexole for motor function and depression in Parkinson&rsquo;s disease
por: Osamu Kano, et al.
Publicado: (2009)

Rasagiline in treatment of Parkinson&rsquo;s disease
por: Lakshmi Nayak, et al.
Publicado: (2008)

A critical review of the recent literature and selected therapy guidelines since 2006 on the use of lamotrigine in bipolar disorder
por: Tr&auml;nkner A, et al.
Publicado: (2013)

Psychosocial therapy for Parkinson's-related dementia: intervention development
por: McCormick SA, et al.
Publicado: (2017)

The effect of cognitive status and visuospatial performance on affective theory of mind in Parkinson's disease
por: McKinlay A, et al.
Publicado: (2013)

Potential sources of stem cells as a regenerative therapy for Parkinson&#39;s disease
por: Abir Oueida El-Sadik
Publicado: (2010)

Aberrantly expressed long noncoding RNAs and genes in Parkinson's disease
por: Zhou Y, et al.
Publicado: (2018)

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
por: Xinhua&nbsp;S Ren, et al.
Publicado: (2009)

Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson's disease
por: Bridoux A, et al.
Publicado: (2013)

Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis
por: Medic G, et al.
Publicado: (2013)

Early and Later Perceptions and Reactions to the COVID-19 Pandemic in Germany: On Predictors of Behavioral Responses and Guideline Adherence During the Restrictions
por: Eva Lermer, et al.
Publicado: (2021)

Current approaches to the treatment of Parkinson&rsquo;s disease
por: Joseph Jankovic, et al.
Publicado: (2008)

Update on ropinirole in the treatment of Parkinson&rsquo;s disease
por: Holly A Shill, et al.
Publicado: (2008)

Efficacy and motor complications of original and generic levodopa in Parkinson's disease treatment
por: Kasemsap N, et al.
Publicado: (2016)

Fluctuating neurological symptoms: should I call the neurologist or the hematologist?
por: Losa-Rodríguez Rita, et al.
Publicado: (2020)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
por: Hametner EM, et al.
Publicado: (2012)